arrow
R

Ralph Wäsch

University of Freiburg
H指数:45
被引数:7,844

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Bridging to CD19 CAR T-cell therapy for large B-cell lymphoma: An analysis of 1,134 patients by the EBMT Lymphoma Working Party and the GoCART Coalition

大型B细胞淋巴瘤桥接CD19 CAR T细胞疗法:EBMT淋巴瘤工作组与GoCART联盟对1,134例患者的分析

2026-11-130
OA
Precision oncology in advanced melanoma: molecular landscapes and personalized therapy recommendations from the Molecular Tumor Board Freiburg

高级黑色素瘤中的精准肿瘤学:来自弗赖堡分子肿瘤委员会的分子景观与个性化治疗建议

2026-10-210
OAAI
Characterisation of TP53 mutational features and outcomes of acute myeloid leukaemia after allogeneic haematopoietic cell transplantation

TP53突变特征及异基因造血细胞移植后急性髓系白血病的结局分析

2026-09-040
OA
Pre–CAR-T B-cell–directed immunotherapy exposure and outcomes after CD19 CAR-T for large B-cell lymphoma: An EBMT registry analysis

CD19 CAR-T治疗前B细胞靶向免疫治疗暴露及大B细胞淋巴瘤患者接受CD19 CAR-T治疗后结局:一项EBMT登记研究

2026-09-010
OAAI
DECIDER-2: Prospective randomized multicenter phase III trial of decitabine and venetoclax administered in combination with all-trans retinoic acid or placebo in patients with acute myeloid leukemia who are ineligible for induction chemotherapy

DECIDER-2:一项前瞻性随机多中心III期临床试验,评估地西他滨联合维奈克拉在所有-trans维甲酸或安慰剂中给予急性髓系白血病患者的疗效,这些患者不适合诱导化疗

2026-08-050
OA
Mutational landscape changes of AML in patients relapsing after allogeneic hematopoietic cell transplantation

异基因造血干细胞移植后复发的AML患者的突变谱变化

2026-04-030
OAAI
Donor lymphocyte infusions for recurrence of myeloid neoplasms after allogeneic hematopoietic cell transplantation in the era of hypomethylating agents and BCL2 inhibitors

在去甲基化药物和BCL2抑制剂时代,异基因造血细胞移植后髓系肿瘤复发的供者淋巴细胞输注

2026-03-300
OAAI
Machine learning-based prediction of one-year mortality after alloHCT identifies the impact of pre-transplant immunity and inflammation

alloHCT后基于机器学习的一年死亡率预测确定了移植前免疫和炎症的影响

2026-01-190
OA
Talquetamab plus daratumumab for the treatment of relapsed or refractory multiple myeloma in the TRIMM-2 study

Talquetamab联合daratumumab治疗复发或难治性多发性骨髓瘤的TRIMM-2研究

Blood
IF23.1
2025-09-240
OA
Influence of daytime of allogeneic stem cell transplantation on incidence of acute graft vs. host disease: a retrospective analytical cohort study

异基因干细胞移植进行时间对急性移植物抗宿主病发生率的影响:一项回顾性分析队列研究

2025-08-020
OAAI
The importance of systemic inflammatory response measurements as pretransplant risk factors for outcome after allogeneic haematopoietic cell transplantation

系统性炎症反应测量作为异基因造血细胞移植后结局的移植前风险因素的重要性

2025-07-290
OA
Remission conversion drives outcomes after CAR T-cell therapy for multiple myeloma: a registry analysis from the DRST

缓解转换驱动多发性骨髓瘤CAR T细胞疗法的结局:来自DRST登记研究的分析

Blood
IF23.1
2025-06-140
OA
Teduglutide for treatment-refractory severe intestinal acute graft-versus-host disease - a multicenter survey

Teduglutide治疗难治性严重肠道急性移植物抗宿主病——一项多中心调查

2025-04-140
OA
Outcome of Patients with Hematologic or Molecular Relapsed/Refractory (R/R) Acute T- Lymphoblastic Leukemia- Data from the GMALL Study Group

造血或分子复发/难治(R/R)急性T淋巴细胞白血病患者的结局—GMALL研究组数据

BLOOD
IF23.1
2024-11-050
PRE